Cidara fails phase 2 study, drops med in vulvovaginal candidiasis

The small cap was down 40% premarket on the news this morning

Cidara Therapeutics will stop work on its antifungal CD101 in women with moderate-to-severe acute vulvovaginal candidiasis (VVC), after the topical candidate failed a mid-stage trial.

The so-called ‘Radiant’ phase 2 tested gel and ointment forms of echinocandin antifungal CD101 in VVC patients against the marketed antifungal fluconazole in an oral form—but failed to show sufficient efficacy. Topical forms of CD101 will not be discontinued, the biotech said in a statement.

“The study found that the gel and ointment topical formulations of CD101 evaluated in Radiant were similar in efficacy to each other but lower in clinical and mycological cure rates compared to oral fluconazole,” the biotech added.

Virtual Roundtable

ESMO Post Show: Highlights From the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields.

It will now focus on an IV version of the drug—currently being studied in phase 2 for candidemia—and the expansion and acceleration of the Cloudbreak immunotherapy platform, which includes CD201 for the treatment of infections caused by multi-drug resistant Gram-negative bacteria.

The IV test, known as the Strive trial, “remains on track,” and is looking at the safety and efficacy of once-weekly CD101 IV to caspofungin, with an optional step-down to oral fluconazole. Results from the test are slated for the fourth quarter of this year.

The small-cap company was pummelled premarket, down 40% to around $7 a share on the news. 

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.